Bristol Myers Squibb Buys Turning Point for US$4.1 B

By Lucy Haggerty

Pharma Deals Review: Vol 2022 Issue 6 (Table of Contents)

Published: 8 Jun-2022

DOI: 10.3833/pdr.v2022.i6.2695     ISSN: 1756-7874

Section: Mergers & Acquisitions



In an attempt to bolster its oncology portfolio, Bristol Myers Squibb (BMS) has entered into an agreement to acquire Turning Point Therapeutics for US$76 per share...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details